KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) EPS (Basic) (2016 - 2025)

Vertex Pharmaceuticals (VRTX) has 17 years of EPS (Basic) data on record, last reported at $4.68 in Q4 2025.

  • For Q4 2025, EPS (Basic) rose 32.58% year-over-year to $4.68; the TTM value through Dec 2025 reached $15.46, up 843.27%, while the annual FY2025 figure was $15.46, 843.27% up from the prior year.
  • EPS (Basic) reached $4.68 in Q4 2025 per VRTX's latest filing, up from $4.24 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $4.68 in Q4 2025 and bottomed at -$13.92 in Q2 2024.
  • Average EPS (Basic) over 5 years is $2.48, with a median of $3.42 recorded in 2021.
  • Peak YoY movement for EPS (Basic): skyrocketed 1119.23% in 2022, then tumbled 492.11% in 2024.
  • A 5-year view of EPS (Basic) shows it stood at $3.01 in 2021, then increased by 5.98% to $3.19 in 2022, then increased by 18.18% to $3.77 in 2023, then decreased by 6.37% to $3.53 in 2024, then surged by 32.58% to $4.68 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were $4.68 in Q4 2025, $4.24 in Q3 2025, and $4.02 in Q2 2025.